Andrew R. Boll
2016
In 2016, Andrew R. Boll earned a total compensation of $1.1M as Chief Financial Officer at Imprimis Pharmaceuticals, a 43% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $84,700 |
|---|---|
| Option Awards | $192,420 |
| Salary | $234,110 |
| Stock Awards | $531,654 |
| Other | $7,396 |
| Total | $1,050,280 |
Boll received $531.7K in stock awards, accounting for 51% of the total pay in 2016.
Boll also received $84.7K in non-equity incentive plan, $192.4K in option awards, $234.1K in salary and $7.4K in other compensation.
Rankings
In 2016, Andrew R. Boll's compensation ranked 8,005th out of 14,075 executives tracked by ExecPay. In other words, Boll earned more than 43.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,005 out of 14,075 | 43rd |
Division Manufacturing | 3,053 out of 5,489 | 44th |
Major group Chemicals And Allied Products | 1,014 out of 1,895 | 47th |
Industry group Drugs | 784 out of 1,538 | 49th |
Industry Pharmaceutical Preparations | 622 out of 1,176 | 47th |
Source: SEC filing on April 27, 2017.
Boll's colleagues
We found two more compensation records of executives who worked with Andrew R. Boll at Imprimis Pharmaceuticals in 2016.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019